Acne Plasma
Acne Plasma - Cryopreserved human plasma from IRB-consented donors with clinically confirmed acne vulgaris, a follicular inflammatory disorder involving sebum production, follicular hyperkeratinization, Cutibacterium acnes, and innate IL-1/IL-17 pathways. Suitable for systemic inflammatory mediator, androgen analyte, proteomic, and metabolomic work. Severity and treatment stratification available.
Acne Plasma for Inflammatory Dermatology Research
Acne Plasma is collected from IRB-consented donors clinically diagnosed with acne vulgaris and processed within one day of collection to preserve labile analytes such as cytokines, proteins, hormones, and metabolites. Cryopreserved and available in custom aliquot volumes. Research Use Only (RUO).
Acne Pathophysiology and What Plasma Can Support
- Acne vulgaris is a disorder of the pilosebaceous unit, not an autoimmune disease. There is no established autoantibody biology in acne, and this page makes no such claim.
- Four processes are well established as central: increased sebum production, follicular hyperkeratinization with comedo formation, colonization of the follicle by Cutibacterium acnes, and an innate inflammatory response involving IL-1 family and IL-17-associated pathways.
- Sebaceous gland activity is androgen-dependent, which is the basis for hormonal treatment approaches. Circulating androgens and related endocrine analytes are therefore measurable and relevant in plasma.
- Acne is fundamentally a localized, follicle-centred inflammatory process. Circulating biomarker biology in acne is genuinely limited, and we deliberately do not claim specific validated plasma biomarkers for the condition.
- Where plasma is useful is for general systemic inflammatory mediator measurement, endocrine and metabolic analyte work, drug and metabolite quantitation, and as a disease-state matrix for assay development. For lesion-level mechanism, tissue is the more appropriate specimen.
Donor Stratification Available
- Severity: mild, moderate, or severe or nodulocystic acne
- Lesion type predominance: comedonal, inflammatory papulopustular, or nodulocystic
- Treatment status: topical retinoid or benzoyl peroxide, systemic antibiotic, isotretinoin, hormonal therapy, or untreated
- Sex and age band, including adolescent and adult-onset acne donors
- Relevant endocrine and metabolic comorbidities such as polycystic ovary syndrome where documented
- Self-reported race/ethnicity and Fitzpatrick skin type where available
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed acne donors
- Processed within one day of collection
- Cryopreserved for long-term stability
- IRB-approved protocols and electronic informed consent, with parental or guardian permission for minors
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified acne diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Severity grade and treatment history where available
- Additional acne-specific metadata available on request
Applications
- Systemic inflammatory mediator and cytokine profiling
- Androgen and endocrine analyte measurement
- Plasma proteomics and untargeted metabolomics
- Lipid and lipidomic analysis
- Exploratory biomarker discovery in inflammatory dermatology
- Pharmacokinetic and drug metabolite quantitation for dermatology candidates
- Disease-state matrix for immunoassay development and validation
- Case-control study designs against matched healthy plasma
Other Acne Specimen Types
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Acne Plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse all matrices and disease states, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.